Work

Low expression of iron–sulfur cluster binding protein RFESD predicts adverse clinical outcomes in acute myeloid leukemia

Year: 2026
Type: article
Abstract: Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive hematopoietic malignancy associated with poor clinical outcomes. In this study, we sought to identify novel biomarkers to improve the diagnosis, treatment and prognosis of AML by integrating transcriptomic and clinical data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) datasets, and the Genotype-Tissue Expression (GTEx) project. RFESD was significantly downregulated in AML and validated as an independent prognostic factor through univariate Cox regression analysis. A survival prediction nomogram was established with a C-index of 0.762, indicating robust predictive performance. Functional pathway enrichment analysis of differentially expressed genes (DEGs) revealed immune response related pathways in low RFESD expression group. Through gene co-expression and protein‒protein interaction (PPI) network analysis, we identified KLF1 as the hub gene, which was linked to adverse clinical outcomes. Finally, drug sensitivity prediction indicated some inhibitors associated with cell-cycle and kinases. Collectively, our findings indicate that low RFESD expression is a predictor of poor prognosis in AML patients.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,690
OpenAlex ID: W7167407547
FWCI:
Cites: 42
Cited by:
Related to: 10